Organon (OGN) Tops Q3 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Organon Reports Results for the Third Quarter Ended September 30, 2021
November 11, 2021 6:31 AM ESTThird quarter 2021 revenue of $1,600 million Net income from continuing operations of $323 million, or $1.27 per diluted share; Adjusted net income from continuing operations of $424Â million, or $1.67 per diluted share Adjusted EBITDA of $636Â million Board of Directors declares quarterly dividend of $0.28 per share Financial guidance affirmed;Â ranges for revenue and Adjusted EBITDA margin, narrowed Executing on business development; announces acquisition of Forendo Pharma
JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN) (the company), today announced its results for the third quarter and year to... More
